SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 or 15d-16 OFTHE SECURITIES EXCHANGE ACT OF 1934
DateMarch 19, 2009_________________________________
BIOTECH HOLDINGS LTD.
(Exact name of Registrant as specified in its charter)
PO Box 48134, RPO Queensborough, New Westminster, British Columbia, Canada, V3M 0A7
(Address of principal executive offices)
Commission file number0-29108 _
(Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F)
Form 20-F Yes Form 40-F No
(Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.)
No
Biotech Holdings Ltd.
Filed in this Form 6-K
Documents index
News Release dated March 19, 2009
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
BIOTECH HOLDINGS LTD.
By: /s/ Lorne Brown
Name: Lorne Brown C.F.O. and Interim C.E.O.
Date: March 19, 2009
Biotech Holdings Ltd. Makes Filing under Insolvency Legislation
Vancouver, B.C., March 19, 2009 - Biotech Holdings Ltd. ("Biotech" or the "Company", OTC BB: BIOHF; Frankfurt: 925970.F) announces that is has been unsuccessful in seeking offers for the merger, sale, refinancing or other strategic alternative for the Company. Consequently, the Company has filed a Notice of Intention to make a proposal for its reorganization under the Bankruptcy and Insolvency Act (Canada). Abakhan & Associates Inc. has consented to act as Trustee under the proposal. In light of the foregoing, the directors of the Company have indicated their intention to resign.
This release has been approved by the Board of Directors of Biotech Holdings.
Biotech Holdings Ltd. is based in Vancouver, British Columbia. Biotech Holdings shares trade on the Over the Counter Bulletin Board in the United States (OTC BB: BIOHF).
For inquiries, contact Gale Belding at Biotech Holdings Ltd., 1 888 216 1111 (toll-free), 8 a.m. to 5 p.m. Pacific time, or by e-mail at biotech@direct.ca. For background information, please visit Biotech`s website at www.biotechltd.com.
This release has been approved by the Board of Directors of Biotech Holdings.
Any statements made in this release that are not based on historical fact are forward-looking statements. Any forward-looking statements made in this release represent management`s best judgement as to what may occur in the future. However, actual outcome and results are not guaranteed and are subject to certain risks, uncertainties and assumptions and may differ materially from what is expressed.
